Grifols (NASDAQ:GRFS) Shares Gap Down - What's Next?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $9.47, but opened at $9.22. Grifols shares last traded at $9.20, with a volume of 295,168 shares changing hands.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a research note on Tuesday, October 29th.

Grifols Stock Down 2.6 %

The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a 50 day simple moving average of $8.88 and a 200 day simple moving average of $8.03.

Institutional Investors Weigh In On Grifols

Institutional investors and hedge funds have recently modified their holdings of the stock. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Grifols in the second quarter worth about $359,000. Sei Investments Co. boosted its position in shares of Grifols by 4.7% in the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company's stock worth $13,931,000 after buying an additional 100,131 shares during the period. Hantz Financial Services Inc. purchased a new stake in shares of Grifols in the second quarter worth about $1,235,000. Natixis Advisors LLC boosted its position in shares of Grifols by 116.0% in the second quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company's stock worth $971,000 after buying an additional 82,723 shares during the period. Finally, Brandes Investment Partners LP boosted its position in shares of Grifols by 8.7% in the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company's stock worth $117,242,000 after buying an additional 1,481,924 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.